

# **NEWSLETTER #1**

## **December 7, 2022**

### **European project CutCancer to facilitate cutting-edge preclinical cancer research in Slovenia**

We are pleased to announce that **the CutCancer project - TWINNING FOR EXCELLENCE TO STRATEGICALLY ADVANCE RESEARCH IN CARCINOGENESIS AND CANCER** - has been selected for funding!

The CutCancer project will enable the implementation of cutting-edge approaches and methodologies that will facilitate frontier research in the field of **preclinical cancer research** in Slovenia.

The project aims to strengthen and increase the research and innovation capacity and excellence of the project coordinator, **the National Institute of Biology in Slovenia**, through targeted twinning activities with three internationally renowned institutions:

- **Swansea University in the United Kingdom**
- **Stockholm University in Sweden and**
- **VU Medical Center Amsterdam in the Netherlands.**

CutCancer will facilitate the application of innovative approaches, including advanced in vitro 3D cell models, high-throughput approaches for genomic instability evaluation, spatial and single-cell analysis, addressing carcinogenesis research and cancer therapeutic resistance research at the National Institute of Biology. The project will encompass the development of synergies between the partner research institutions, fostering networking and participation in future Research and Innovation processes.

#### **Project summary and numbers**

**Name:** CutCancer - TWINNING FOR EXCELLENCE TO STRATEGICALLY ADVANCE RESEARCH IN CARCINOGENESIS AND CANCER

**EU call and number:** HORIZON-WIDERA -2021- ACCESS -03 (Twinning),

101079113

**Coordinator:** National Institute of Biology, Slovenia

**Partners:** 4

**Starting date:** January 1, 2023

**Duration:** 36 months

**Budget:** 1,197,550 €



**Funded by  
the European Union**

